Destiny Pharma (LSE:DEST) EBIT : £-6.74 Mil (TTM As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Destiny Pharma EBIT?

Destiny Pharma's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was £-3.49 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was £-6.74 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Destiny Pharma's annualized ROC % for the quarter that ended in Dec. 2023 was -230.97%. Destiny Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -3,715.96%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Destiny Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -77.77%.

Destiny Pharma EBIT Historical Data

The historical data trend for Destiny Pharma's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Destiny Pharma EBIT Chart

Destiny Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-5.54

-6.55

-6.29

-7.78

-6.74

Destiny Pharma Semi-Annual Data
	Dec14	Dec15	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT	Get a 7-Day Free Trial												-3.30	-3.81	-3.96	-3.24	-3.49

Competitive Comparison of Destiny Pharma's EBIT

For the Biotechnology subindustry, Destiny Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Destiny Pharma's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Destiny Pharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Destiny Pharma's EV-to-EBIT falls into.

Destiny Pharma EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-6.74 Mil.

Destiny Pharma (LSE:DEST) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Destiny Pharma's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-6.986 * ( 1 - 9.56% )	/	( (2.363	+	3.108)	/ 2 )
=	-6.3181384	/	2.7355
=	-230.97 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	13.046	-	1.127	-	( 9.843	-	max(0, 1.127	-	10.683	+	9.843	))
=	2.363

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	9.957	-	0.466	-	( 6.383	-	max(0, 0.768	-	7.597	+	6.383	))
=	3.108

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Destiny Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-6.986	/	( ( (0.022 + max(-1.127, 0))	+	(0.019 + max(0.335, 0)) )	/	2 )
=	-6.986	/	( ( 0.022	+	0.354 )	/	2 )
=	-6.986	/	0.188
=	-3,715.96 %

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0)	-	(1.127	+	0	+	0)
=	-1.127

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	1.103)	-	(0.466	+	0	+	0.302)
=	0.335

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Destiny Pharma's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-6.736	/	8.661
	=	-77.77 %

Destiny Pharma EBIT Related Terms

Thank you for viewing the detailed overview of Destiny Pharma's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Destiny Pharma (LSE:DEST) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Destiny Pharma PLC (LSE:DEST) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

D89:Germany

Address

Unit 36, Sussex Innovation Centre, Science Park Square, Falmer, Brighton, GBR, BN1 9SB

Website

https://www.destinypharma.com

Destiny Pharma PLC is a clinical-stage biotechnology company which is focused on the development of medicines for the treatment of infectious disease. It is developing drugs for the prevention and treatment of infections caused by Antibiotic-Resistant (AR) bacteria. It is involved in developing XF-73 Dermal for the treatment of skin infections of antibiotic-resistant bacteria, XF-73 Nasal for prevention of post-surgical staphylococcal infection, XF Throat for prevention of staphylococcal hospital/ventilator-associated pneumonia infection.

Destiny Pharma (LSE:DEST) Headlines

No Headlines